Is CLLS or URGN more profitable?

Cellectis has a net margin of -89.51% compared to Urogen Pharma's net margin of -94.83%. Urogen Pharma's return on equity of 0.00% beat Cellectis' return on equity. Company Net Margins Return on Equity Return on Assets Cellectis -89.51% -80.66% -20.51% Urogen Pharma -94.83% N/A -62.85%

Does the media favor CLLS or URGN?

In the previous week, Urogen Pharma had 2 more articles in the media than Cellectis. MarketBeat recorded 5 mentions for Urogen Pharma and 3 mentions for Cellectis. Cellectis' average media sentiment score of 1.44 beat Urogen Pharma's score of 0.47 indicating that Cellectis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Urogen Pharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CLLS or MAZE?

In the previous week, Maze Therapeutics had 2 more articles in the media than Cellectis. MarketBeat recorded 5 mentions for Maze Therapeutics and 3 mentions for Cellectis. Cellectis' average media sentiment score of 1.44 beat Maze Therapeutics' score of 0.22 indicating that Cellectis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maze Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BCAX or CLLS?

In the previous week, Bicara Therapeutics had 4 more articles in the media than Cellectis. MarketBeat recorded 7 mentions for Bicara Therapeutics and 3 mentions for Cellectis. Cellectis' average media sentiment score of 1.44 beat Bicara Therapeutics' score of 0.22 indicating that Cellectis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cellectis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SLS or CLLS?

In the previous week, SELLAS Life Sciences Group had 3 more articles in the media than Cellectis. MarketBeat recorded 6 mentions for SELLAS Life Sciences Group and 3 mentions for Cellectis. Cellectis' average media sentiment score of 1.44 beat SELLAS Life Sciences Group's score of 0.55 indicating that Cellectis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cellectis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer KALV or CLLS?

In the previous week, KalVista Pharmaceuticals had 1 more articles in the media than Cellectis. MarketBeat recorded 4 mentions for KalVista Pharmaceuticals and 3 mentions for Cellectis. Cellectis' average media sentiment score of 1.44 beat KalVista Pharmaceuticals' score of 0.62 indicating that Cellectis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KalVista Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cellectis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cellectis (CLLS) Competitors

$3.09 -0.29 (-8.58%)

Closing price 04:00 PM Eastern

Extended Trading

$3.11 +0.02 (+0.65%)

As of 07:14 PM Eastern

Compare

CLLS vs. URGN, MAZE, BCAX, SLS, and KALV

Should you buy Cellectis stock or one of its competitors? MarketBeat compares Cellectis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cellectis include Urogen Pharma (URGN), Maze Therapeutics (MAZE), Bicara Therapeutics (BCAX), SELLAS Life Sciences Group (SLS), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical products" industry.

How does Cellectis compare to Urogen Pharma?

Cellectis (NASDAQ:CLLS) and Urogen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

63.9% of Cellectis shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 16.4% of Cellectis shares are owned by company insiders. Comparatively, 4.7% of Urogen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cellectis currently has a consensus target price of $7.00, suggesting a potential upside of 126.54%. Urogen Pharma has a consensus target price of $36.67, suggesting a potential upside of 37.84%. Given Cellectis' stronger consensus rating and higher possible upside, analysts clearly believe Cellectis is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Cellectis has higher earnings, but lower revenue than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	3.90	-$67.59M	-$0.67	N/A
Urogen Pharma	$109.79M	11.80	-$153.49M	-$2.75	N/A

Cellectis has a beta of 2.86, meaning that its share price is 186% more volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market.

In the previous week, Urogen Pharma had 2 more articles in the media than Cellectis. MarketBeat recorded 5 mentions for Urogen Pharma and 3 mentions for Cellectis. Cellectis' average media sentiment score of 1.44 beat Urogen Pharma's score of 0.47 indicating that Cellectis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Urogen Pharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cellectis has a net margin of -89.51% compared to Urogen Pharma's net margin of -94.83%. Urogen Pharma's return on equity of 0.00% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-89.51%	-80.66%	-20.51%
Urogen Pharma	-94.83%	N/A	-62.85%

Summary

Cellectis beats Urogen Pharma on 10 of the 16 factors compared between the two stocks.

How does Cellectis compare to Maze Therapeutics?

Cellectis (NASDAQ:CLLS) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

Cellectis presently has a consensus price target of $7.00, suggesting a potential upside of 126.54%. Maze Therapeutics has a consensus price target of $66.00, suggesting a potential upside of 165.49%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Maze Therapeutics is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Maze Therapeutics had 2 more articles in the media than Cellectis. MarketBeat recorded 5 mentions for Maze Therapeutics and 3 mentions for Cellectis. Cellectis' average media sentiment score of 1.44 beat Maze Therapeutics' score of 0.22 indicating that Cellectis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maze Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Maze Therapeutics has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. Maze Therapeutics' return on equity of -36.62% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-89.51%	-80.66%	-20.51%
Maze Therapeutics	N/A	-36.62%	-31.78%

Cellectis has a beta of 2.86, meaning that its share price is 186% more volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.26, meaning that its share price is 126% more volatile than the broader market.

63.9% of Cellectis shares are owned by institutional investors. 16.4% of Cellectis shares are owned by insiders. Comparatively, 5.3% of Maze Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cellectis has higher earnings, but lower revenue than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	3.90	-$67.59M	-$0.67	N/A
Maze Therapeutics	$167.50M	8.21	-$131.12M	-$2.53	N/A

Summary

Maze Therapeutics beats Cellectis on 9 of the 17 factors compared between the two stocks.

How does Cellectis compare to Bicara Therapeutics?

Bicara Therapeutics (NASDAQ:BCAX) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

63.9% of Cellectis shares are owned by institutional investors. 13.8% of Bicara Therapeutics shares are owned by company insiders. Comparatively, 16.4% of Cellectis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Bicara Therapeutics had 4 more articles in the media than Cellectis. MarketBeat recorded 7 mentions for Bicara Therapeutics and 3 mentions for Cellectis. Cellectis' average media sentiment score of 1.44 beat Bicara Therapeutics' score of 0.22 indicating that Cellectis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicara Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cellectis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bicara Therapeutics has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. Bicara Therapeutics' return on equity of -35.89% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-35.89%	-33.78%
Cellectis	-89.51%	-80.66%	-20.51%

Cellectis has higher revenue and earnings than Bicara Therapeutics. Bicara Therapeutics is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A
Cellectis	$79.59M	3.90	-$67.59M	-$0.67	N/A

Bicara Therapeutics has a beta of -0.53, indicating that its share price is 153% less volatile than the broader market. Comparatively, Cellectis has a beta of 2.86, indicating that its share price is 186% more volatile than the broader market.

Bicara Therapeutics presently has a consensus target price of $30.27, indicating a potential upside of 51.40%. Cellectis has a consensus target price of $7.00, indicating a potential upside of 126.54%. Given Cellectis' stronger consensus rating and higher probable upside, analysts plainly believe Cellectis is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Cellectis beats Bicara Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Cellectis compare to SELLAS Life Sciences Group?

SELLAS Life Sciences Group (NASDAQ:SLS) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

SELLAS Life Sciences Group currently has a consensus price target of $10.00, suggesting a potential upside of 22.10%. Cellectis has a consensus price target of $7.00, suggesting a potential upside of 126.54%. Given Cellectis' stronger consensus rating and higher possible upside, analysts plainly believe Cellectis is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 1.3% of SELLAS Life Sciences Group shares are held by company insiders. Comparatively, 16.4% of Cellectis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

SELLAS Life Sciences Group has a beta of 2.5, meaning that its stock price is 150% more volatile than the broader market. Comparatively, Cellectis has a beta of 2.86, meaning that its stock price is 186% more volatile than the broader market.

In the previous week, SELLAS Life Sciences Group had 3 more articles in the media than Cellectis. MarketBeat recorded 6 mentions for SELLAS Life Sciences Group and 3 mentions for Cellectis. Cellectis' average media sentiment score of 1.44 beat SELLAS Life Sciences Group's score of 0.55 indicating that Cellectis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cellectis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SELLAS Life Sciences Group has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. SELLAS Life Sciences Group's return on equity of -47.12% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%
Cellectis	-89.51%	-80.66%	-20.51%

SELLAS Life Sciences Group has higher earnings, but lower revenue than Cellectis. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A
Cellectis	$79.59M	3.90	-$67.59M	-$0.67	N/A

Summary

Cellectis beats SELLAS Life Sciences Group on 11 of the 16 factors compared between the two stocks.

How does Cellectis compare to KalVista Pharmaceuticals?

KalVista Pharmaceuticals (NASDAQ:KALV) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

In the previous week, KalVista Pharmaceuticals had 1 more articles in the media than Cellectis. MarketBeat recorded 4 mentions for KalVista Pharmaceuticals and 3 mentions for Cellectis. Cellectis' average media sentiment score of 1.44 beat KalVista Pharmaceuticals' score of 0.62 indicating that Cellectis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
KalVista Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cellectis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

KalVista Pharmaceuticals has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. Cellectis' return on equity of -80.66% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%
Cellectis	-89.51%	-80.66%	-20.51%

Cellectis has higher revenue and earnings than KalVista Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KalVista Pharmaceuticals	$49.08M	29.23	-$109.52M	-$3.46	N/A
Cellectis	$79.59M	3.90	-$67.59M	-$0.67	N/A

KalVista Pharmaceuticals has a beta of -0.12, meaning that its stock price is 112% less volatile than the broader market. Comparatively, Cellectis has a beta of 2.86, meaning that its stock price is 186% more volatile than the broader market.

KalVista Pharmaceuticals presently has a consensus target price of $30.60, suggesting a potential upside of 13.56%. Cellectis has a consensus target price of $7.00, suggesting a potential upside of 126.54%. Given Cellectis' stronger consensus rating and higher probable upside, analysts clearly believe Cellectis is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

63.9% of Cellectis shares are owned by institutional investors. 4.3% of KalVista Pharmaceuticals shares are owned by insiders. Comparatively, 16.4% of Cellectis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Cellectis beats KalVista Pharmaceuticals on 14 of the 17 factors compared between the two stocks.

Get Cellectis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLLS vs. The Competition

Export

Metric	Cellectis	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$310.05M	$3.28B	$6.45B	$12.42B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	-4.61	17.93	22.30	24.19
Price / Sales	3.90	324.62	581.44	138.36
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	4.07	6.63	9.84	6.72
Net Income	-$67.59M	$24.20M	$3.57B	$337.19M
7 Day Performance	-14.88%	-3.24%	-1.16%	0.48%
1 Month Performance	-21.77%	0.53%	3.85%	5.07%
1 Year Performance	111.64%	47.24%	27.40%	34.25%

Cellectis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLLS Cellectis	3.0855 of 5 stars	$3.09 -8.6%	$7.00 +126.5%	+126.8%	$310.05M	$79.59M	N/A	290	Gap Up High Trading Volume
URGN Urogen Pharma	3.5035 of 5 stars	$29.75 +3.0%	$36.67 +23.2%	+448.3%	$1.45B	$109.79M	N/A	200	Analyst Forecast
MAZE Maze Therapeutics	2.9791 of 5 stars	$26.17 +1.5%	$66.00 +152.2%	+100.7%	$1.45B	$167.50M	N/A	121
BCAX Bicara Therapeutics	2.089 of 5 stars	$21.87 +0.9%	$30.27 +38.4%	+98.4%	$1.44B	N/A	N/A	32	Analyst Revision
SLS SELLAS Life Sciences Group	1.8339 of 5 stars	$7.71 -0.9%	$10.00 +29.7%	+427.2%	$1.43B	N/A	N/A	10	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLLS) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cellectis (CLLS) Competitors

CLLS vs. URGN, MAZE, BCAX, SLS, and KALV

How does Cellectis compare to Urogen Pharma?

Summary

How does Cellectis compare to Maze Therapeutics?

Summary

How does Cellectis compare to Bicara Therapeutics?

Summary

How does Cellectis compare to SELLAS Life Sciences Group?

Summary

How does Cellectis compare to KalVista Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLLS vs. The Competition

Cellectis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cellectis (CLLS) Competitors

CLLS vs. URGN, MAZE, BCAX, SLS, and KALV

How does Cellectis compare to Urogen Pharma?

Do insiders and institutionals have more ownership in CLLS or URGN?

Do analysts rate CLLS or URGN?

Which has higher earnings and valuation, CLLS or URGN?

Which has more risk & volatility, CLLS or URGN?

Does the media favor CLLS or URGN?

Is CLLS or URGN more profitable?

Summary

How does Cellectis compare to Maze Therapeutics?

Do analysts rate CLLS or MAZE?

Does the media favor CLLS or MAZE?

Is CLLS or MAZE more profitable?

Which has more volatility & risk, CLLS or MAZE?

Do insiders & institutionals have more ownership in CLLS or MAZE?

Which has preferable earnings & valuation, CLLS or MAZE?

Summary

How does Cellectis compare to Bicara Therapeutics?

Do institutionals and insiders have more ownership in BCAX or CLLS?

Does the media favor BCAX or CLLS?

Is BCAX or CLLS more profitable?

Which has preferable earnings and valuation, BCAX or CLLS?

Which has more volatility & risk, BCAX or CLLS?

Do analysts recommend BCAX or CLLS?

Summary

How does Cellectis compare to SELLAS Life Sciences Group?

Do analysts prefer SLS or CLLS?

Do institutionals & insiders have more ownership in SLS or CLLS?

Which has more risk and volatility, SLS or CLLS?

Does the media refer more to SLS or CLLS?

Is SLS or CLLS more profitable?

Which has higher earnings & valuation, SLS or CLLS?

Summary

How does Cellectis compare to KalVista Pharmaceuticals?

Does the media prefer KALV or CLLS?

Is KALV or CLLS more profitable?

Which has preferable valuation & earnings, KALV or CLLS?

Which has more volatility and risk, KALV or CLLS?

Do analysts prefer KALV or CLLS?

Do insiders & institutionals have more ownership in KALV or CLLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLLS vs. The Competition

Cellectis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools